<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641093</url>
  </required_header>
  <id_info>
    <org_study_id>UCCI-HN-15-01</org_study_id>
    <nct_id>NCT02641093</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trisha Wise-Draper</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the safety and the benefit of adding&#xD;
      pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of&#xD;
      care treatment for head and neck cancer. The standard of care treatment will include surgery&#xD;
      followed by radiation for 6 weeks. Some patients may also receive cisplatin as standard of&#xD;
      care once a week for 6 weeks if the cancer is found to be &quot;high risk&quot;. High risk includes&#xD;
      cancer that was not completely removed (positive margins) or cancer that has invaded through&#xD;
      the outer lining of your lymph nodes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Actual">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment related adverse effects as assessed using CTCAE v4.0 of pembrolizumab when combined with radiation alone and chemoradiation</measure>
    <time_frame>30 days following completion of treatment</time_frame>
    <description>Compare percentage of grade 3 and 4 adverse events with historical control percentages.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival in resected high risk patients treated with adjuvant pembrolizumab and chemoradiation</measure>
    <time_frame>1 and 3 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival in resected intermediate risk patients treated with adjuvant pembrolizumab and radiation</measure>
    <time_frame>1 and 3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor immune response to pembrolizumab as measured by immunohistochemistry in tumor tissue before and after treatment</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab in combination with standard of care surgery followed by radiation therapy with or without cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>gross total surgical resection</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>60-66 Gy over 6 weeks</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Weekly during radiation therapy for 6 doses only for patients with high risk pathological features</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients eligible for resection with one or more of the following&#xD;
&#xD;
               1. Any T stage with â‰¥ N2 disease;&#xD;
&#xD;
               2. T4 disease, any N stage;&#xD;
&#xD;
               3. T3 Oral Cavity, any N stage; or&#xD;
&#xD;
               4. Clinical evidence of extra-capsular extension on scans.&#xD;
&#xD;
          -  Must be willing to undergo definitive resection with neck dissection.&#xD;
&#xD;
          -  Performance status 0 or 1 on Eastern Cooperative Oncology Group Performance Scale.&#xD;
&#xD;
          -  Adequate labs&#xD;
&#xD;
          -  Appropriate staging imaging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or receiving systemic steroid therapy or&#xD;
             immunosuppressive therapy within 7 days prior to planned first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          -  Nasopharyngeal or sinonasal carcinoma&#xD;
&#xD;
          -  Confirmed metastatic disease&#xD;
&#xD;
          -  Human Papillomavirus (HPV)+ disease of the oropharynx&#xD;
&#xD;
          -  Known history of active tuberculosis (TB), autoimmune disease, pneumonitis, infection,&#xD;
             HIV, Hepatitis B, or Hepatitis C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trisha Wise-Draper, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville - James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Trisha Wise-Draper</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

